Jacobs Levy Equity Management’s Theravance Biopharma TBPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-30,444
| Closed | -$570K | – | 1064 |
|
|
2025
Q4 | $570K | Sell |
30,444
-10,094
| -25% | -$167K | ﹤0.01% | 777 |
|
|
2025
Q3 | $592K | Buy |
40,538
+20,364
| +101% | +$257K | ﹤0.01% | 797 |
|
|
2025
Q2 | $223K | Sell |
20,174
-141,623
| -88% | -$1.38M | ﹤0.01% | 971 |
|
|
2025
Q1 | $1.44M | Sell |
161,797
-276,666
| -63% | -$2.57M | 0.01% | 730 |
|
|
2024
Q4 | $4.13M | Sell |
438,463
-137,984
| -24% | -$1.26M | 0.01% | 465 |
|
|
2024
Q3 | $4.65M | Sell |
576,447
-10,167
| -2% | -$88.1K | 0.02% | 452 |
|
|
2024
Q2 | $4.97M | Buy |
586,614
+28,643
| +5% | +$259K | 0.02% | 458 |
|
|
2024
Q1 | $5M | Buy |
557,971
+163,951
| +42% | +$1.52M | 0.02% | 428 |
|
|
2023
Q4 | $4.43M | Sell |
394,020
-13,505
| -3% | -$136K | 0.02% | 445 |
|
|
2023
Q3 | $3.52M | Sell |
407,525
-190,039
| -32% | -$1.83M | 0.02% | 445 |
|
|
2023
Q2 | $6.18M | Sell |
597,564
-413,125
| -41% | -$4.56M | 0.04% | 352 |
|
|
2023
Q1 | $11M | Sell |
1,010,689
-21,625
| -2% | -$229K | 0.07% | 271 |
|
|
2022
Q4 | $11.6M | Buy |
1,032,314
+204,408
| +25% | +$2.15M | 0.08% | 261 |
|
|
2022
Q3 | $8.39M | Sell |
827,906
-31,700
| -4% | -$297K | 0.07% | 292 |
|
|
2022
Q2 | $7.79M | Sell |
859,606
-182,348
| -18% | -$1.68M | 0.06% | 330 |
|
|
2022
Q1 | $9.96M | Buy |
1,041,954
+19,026
| +2% | +$186K | 0.07% | 295 |
|
|
2021
Q4 | $11.3M | Buy |
1,022,928
+377,051
| +58% | +$3.29M | 0.08% | 276 |
|
|
2021
Q3 | $4.78M | Buy |
645,877
+54,353
| +9% | +$608K | 0.03% | 445 |
|
|
2021
Q2 | $8.59M | Buy |
591,524
+31,610
| +6% | +$594K | 0.06% | 330 |
|
|
2021
Q1 | $11.4M | Sell |
559,914
-6,026
| -1% | -$115K | 0.09% | 262 |
|
|
2020
Q4 | $10.1M | Sell |
565,940
-23,996
| -4% | -$431K | 0.09% | 259 |
|
|
2020
Q3 | $8.72M | Buy |
589,936
+101,829
| +21% | +$1.91M | 0.09% | 234 |
|
|
2020
Q2 | $10.2M | Buy |
488,107
+71,165
| +17% | +$1.83M | 0.11% | 212 |
|
|
2020
Q1 | $9.64M | Sell |
416,942
-35,673
| -8% | -$893K | 0.12% | 188 |
|
|
2019
Q4 | $11.7M | Buy |
452,615
+71,060
| +19% | +$1.38M | 0.12% | 218 |
|
|
2019
Q3 | $7.43M | Buy |
381,555
+71,682
| +23% | +$1.45M | 0.09% | 265 |
|
|
2019
Q2 | $5.06M | Buy |
309,873
+41,060
| +15% | +$832K | 0.07% | 344 |
|
|
2019
Q1 | $6.09M | Buy |
268,813
+94,070
| +54% | +$2.39M | 0.09% | 295 |
|
|
2018
Q4 | $4.47M | Buy |
174,743
+4,080
| +2% | +$110K | 0.08% | 287 |
|
|
2018
Q3 | $5.58M | Sell |
170,663
-27,158
| -14% | -$740K | 0.08% | 292 |
|
|
2018
Q2 | $4.49M | Buy |
197,821
+127,422
| +181% | +$3.03M | 0.07% | 328 |
|
|
2018
Q1 | $1.71M | Buy |
70,399
+54,899
| +354% | +$1.51M | 0.03% | 512 |
|
|
2017
Q4 | $432K | Buy |
+15,500
| New | +$459K | 0.01% | 783 |
|
|
2016
Q3 | – | Sell |
-21,100
| Closed | -$479K | – | 1126 |
|
|
2016
Q2 | $479K | Buy |
+21,100
| New | +$456K | 0.01% | 769 |
|
Other funds holding TBPH
MAP
WAM
NM
ICM
VCM
Jacobs Levy Equity Management's TBPH Position: Q1 2026 in Review
Jacobs Levy Equity Management sold out of Theravance Biopharma (TBPH) in Q1 2026, closing a stake of 30,444 shares — an estimated $570K sold.
Jacobs Levy Equity Management first reported a position in TBPH in Q2 2016 and held it in 34 quarters. The position peaked at $11.7M in Q4 2019. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.
- Jacobs Levy Equity Management reported no remaining Theravance Biopharma position as of Q1 2026 after selling out during the quarter.
- Jacobs Levy Equity Management sold 30,444 Theravance Biopharma shares in Q1 2026, an estimated $570K.
- Jacobs Levy Equity Management first reported a position in Theravance Biopharma in Q2 2016 and held it in 34 quarters.
- Jacobs Levy Equity Management's Theravance Biopharma position peaked at $11.7M in Q4 2019.
- 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.
Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.